Loading clinical trials...

Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea | Clinical Trials | Clareo Health

UNKNOWN

Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea

Relevance of the Ratio Kynurenine/Tryptophan to Characterize Hypertension Associated to Obstructive Sleep Apnea (KYNTOSA)

NCT04646902•Universidade Nova de Lisboa

View on ClinicalTrials.gov

Summary

Obstructive Sleep Apnea (OSA) is an independent risk factor for hypertension (HTN) and the most common cause of resistant HTN. The mechanisms underlying OSA-associated HTN are not completely understood. This is crucial to find novel therapeutic targets of OSA-associated HTN. The Aryl Hydrocarbon Receptor (AHR) is a cytosolic transcription factor that has been linked with the pathogenesis of HTN. This study aims to evaluate the role of endogenous ligands of AHR such as kynurenine in discriminating patients with OSA-associated HTN. For that aim, a case-control study will be performed in patients with and without hypertension exposed and not exposed to OSA. Kynurenine and other metabolites will be quantified in urine and serum samples.

Eligibility

Age

30 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•CASES (subjects with hypertension with and without OSA)
•Adults ≥ 30 years old attending the outpatient clinics of the clinical sites.
•Diagnosis of hypertension defined either as: a) use of antihypertensive drug(s) and stable dose for at least 2 weeks prior to inclusion; or b) in untreated patients: office systolic blood pressure values \>= 140 mmHg and/ or diastolic blood pressure values \>= 90 mmHg.
•Able to understand and communicate effectively with study personnel.
•Giving written informed consent to participate.

Exclusion Criteria

•Self-reported pregnancy or breastfeeding.
•Patients on haemodialysis or peritoneal dialysis.
•Chronic liver disease with Child-Pugh score B or higher.
•Hypertension attributed to renal artery stenosis, primary hyperaldosteronism, pheochromocytoma, Cushing's syndrome, coarctation of aorta.
•History of any OSA surgical treatment to the palatal and hypopharyngeal regions, notably uvulopalatopharyngoplasty surgery (UPPP), palatal radio frequency ablation, tonsillectomy, lingual tonsillectomy, partial glossectomy, tongue base radio frequency ablation, genioglossal advancement, hyoid suspension, maxillomandibular advancement surgery (MMA) and active use of hypoglossal nerve stimulator.
•Patients with a good adherence to CPAP, defined as the use of CPAP for at least 4 hours/night on 70% of nights during the last 3 months.
•Pulmonary hypertension.
•Current diagnosed oncological disease.
•Patients with known chronic or acute infectious diseases.
•Other current severe progressive or uncontrolled disease which in the judgement of the investigator renders the patient unsuitable for the study
+11 more criteria

Locations (5)

Centro Hospitalar de Lisboa Central

Lisbon, Portugal

Centro Hospitalar Lisboa Ocidental

Lisbon, Portugal

Hospital Beatriz Ângelo

Lisbon, Portugal

Hospital da Luz

Lisbon, Portugal

Hospital Fernando Fonseca

Lisbon, Portugal

Key Dates

Start Date

March 25, 2021

Primary Completion Date

September 1, 2023

Completion Date

March 1, 2024

Last Updated

December 7, 2023

Enrollment

203

ACTUAL participants

Conditions

Hypertension Secondary

Hypertension as a Reason for Concellation of Elective Minor Abdominal Surgery

NCT06628648

Hypertension SecondarySurgery

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions